Early Serum Infliximab Levels in Severe Ulcerative Colitis.
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to a.) evaluate whether early serum infliximab levels are predictive
of avoidance of colectomy, b) evaluate whether serum albumin levels correlate with serum
infliximab levels, and c) evaluate whether serum tumor necrosis factor levels are inversely
correlated with serum infliximab levels.
In patients hospitalized for severe ulcerative colitis and treated with high-dose infliximab,
we predict that early serum infliximab levels (24, 48, and 72 hour) will be positively
associated with clinical response and avoidance of colectomy.